We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Before prescribing hormone-replacement therapy, healthcare professionals should consider carefully the potential benefits and risks for every woman
An Expert Working Group (EWG) of the UK’s Commission on Human Medicines (CHM) has published their report on the use of hormone pregnancy tests (HPTs) and adverse effects relating to pregnancy including possible birth defects.
MHRA statement in response to the study in The Lancet on the use of HRT.
Membership and minutes for the Commission on Human Medicines (CHM) and its expert advisory groups (EAGs).
Government action to cut the cost of repeatable HRT prescriptions and a new Menopause Taskforce means women experiencing the menopause will be better supported.
Head of the HRT Taskforce Madelaine McTernan presents key recommendations for future management of hormone replacement therapy (HRT) supply.
Women who are current or past users of hormone replacement therapy (HRT) to treat symptoms of the menopause are reminded to be vigilant for signs of breast cancer, even after stopping HRT.
Action taken as suppliers increase stocks of hormone replacement therapy (HRT) products.
Urgent action continues to be taken to ensure women across the UK will be able to more reliably access HRT products.
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).